NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences Inc (NYSE:RCUS) announced its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. The firm earned $1.75 million during the quarter, compared to the consensus estimate of $1.34 million. Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. View Arcus Biosciences' Earnings History.

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

5 brokerages have issued 1 year price objectives for Arcus Biosciences' stock. Their forecasts range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' stock price to reach $19.25 in the next year. This suggests a possible upside of 118.5% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

Media stories about RCUS stock have trended somewhat negative recently, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcus Biosciences earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Arcus Biosciences.

Arcus Biosciences saw a drop in short interest during the month of November. As of November 29th, there was short interest totalling 1,390,000 shares, a drop of 12.0% from the November 14th total of 1,580,000 shares. Based on an average daily trading volume, of 231,500 shares, the short-interest ratio is currently 6.0 days. Currently, 5.5% of the company's stock are sold short. View Arcus Biosciences' Current Options Chain.

Some companies that are related to Arcus Biosciences include Myovant Sciences (MYOV), Nabriva Therapeutics (NBRV), Esperion Therapeutics (ESPR), Y-mAbs Therapeutics (YMAB), Innoviva (INVA), Athenex (ATNX), Arvinas (ARVN), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Principia Biopharma (PRNB), Constellation Pharmaceuticals (CNST), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Spectrum Pharmaceuticals (SPPI) and Supernus Pharmaceuticals (SUPN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), Fate Therapeutics (FATE), Galmed Pharmaceuticals (GLMD), Vale (VALE), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), BIOLINERX LTD/S (BLRX) and Cidara Therapeutics (CDTX).

(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.35%), Millennium Management LLC (0.41%), Parallel Advisors LLC (0.19%), California State Teachers Retirement System (0.11%), Rhumbline Advisers (0.11%) and Barclays PLC (0.05%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.

RCUS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Bailard Inc.. View Insider Buying and Selling for Arcus Biosciences.

RCUS stock was bought by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, Millennium Management LLC, State Street Corp, California Public Employees Retirement System, Russell Investments Group Ltd., Rhumbline Advisers, Meeder Asset Management Inc. and California State Teachers Retirement System. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $8.81.

Arcus Biosciences has a market capitalization of $404.02 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

The official website for Arcus Biosciences is http://www.arcusbio.com/.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]